FAIMS Breathalyzer Device

The Company is working to advance its FAIMS technology for the medical device market. FAIMS is a new form of atmospheric pressure ion separation technology.

Medical testing based on FAIMS technology, could allow for the miniaturization of breath testing devices enabling real time, point of care (POC) non-invasive and accurate clinical screening of human breath.

Research shows that human breath contains biomarkers that may be differentially expressed in people who have a specific disease condition compared to healthy individuals. Real time, accurate POC screening of human breath could provide the medical community with a new tool to help screen and possibly diagnose a wide range of human diseases.

It is generally regarded within the global breath research community, that a portable, POC breathalyzer device, that can accurately identify and quantify human breath biomarkers in real-time, could dramatically enhance and improve the current research landscape. This advancement could possibly lead the way to regulatory approved testing.

On November 5th, 2018, the Company announced that it amended its research agreement with the University of Florida’s Analytical Chemistry Department, where Dr. Richard Yost, the Principal Investigator, will work to advance its current design prototype, the V3, or future iterations, through its final stages of prototype development.  Dr. Yost is one of the world’s foremost experts on FAIMS technology and has been a scientific advisor with the Company since 2016.

Before the V3 prototype development phase is successfully completed, the device will need to achieve a number of performance characteristics including device sensitivity, precision and reproducibility in a laboratory setting. Once the prototype work is completed, the device will be ready to be moved into a research use only (RUO) development phase. The goal of this phase will be to engineer and produce field ready devices that will be made available to research scientists worldwide to help advance the discovery and validation of breath-based biomarkers.